ThreeWeek Radiation Therapy Treatment PostMastectomy Safe and Effective


first_img News | PACS | August 09, 2019 Lake Medical Imaging Selects Infinitt for Multi-site RIS/PACS Infinitt North America will be implementing Infinitt RIS (radiology information system)/PACS (picture archiving and… read more The MD Anderson Proton Therapy Center expansion is expected to be completed in 2023. Rendering courtesy of Stantec. Following radiation, the bone marrow shows nearly complete loss of blood cells in mice (left). Mice treated with the PTP-sigma inhibitor displayed rapid recovery of blood cells (purple, right). Credit: UCLA Broad Stem Cell Research Center/Nature Communications May 2, 2017 — A shorter course of radiation therapy given to breast cancer patients following mastectomy is safe and effective and cuts treatment time in half. That is according to data from a phase II clinical trial conducted by Rutgers Cancer Institute of New Jersey investigators and other colleagues who examined a hypofractionated regimen given over three weeks versus the traditional six week course of treatment. The work appears in the current online edition of the Journal of Clinical Oncology.When there is a concern that cancer cells may remain in the chest wall and lymph node regions following a mastectomy, a patient may be given targeted radiation over a five- to six-week period to further treat the breast cancer. “Receiving radiation for that long of a period becomes a quality of life issue for many patients. This includes the inconvenience of frequent travel to the treatment facility, as well as fatigue and other common side effects that can cause lost time at work and other challenges,” noted the work’s senior investigator Bruce G. Haffty, M.D., professor and chair, Department of Radiation Oncology at Rutgers Cancer Institute, Rutgers Robert Wood Johnson Medical School and Rutgers New Jersey Medical School.  Researchers explored an accelerated course of radiation that cut treatment time in half. Currently, there is limited data supporting this type of treatment in this patient population.From 2010 to 2014, 67 eligible patients with stage II to IIIa breast cancer were enrolled at Rutgers Cancer Institute of New Jersey and Huntsman Cancer Institute at the University of Utah. A dose of 36.63 Gy (a unit of radiation measurement) was given in 11 fractions of 3.33 Gy each. The fractions were delivered over a three-week period to the chest wall and area lymph nodes. The treatment also allowed for an optional four fractions (3.33 Gy each) of radiation to the chest wall at the mastectomy scar area, resulting in a total of 15 treatments over three weeks. The aim was to not have any reported treatment toxicities of grade three or above. After a median follow up of 32 months, no grade three toxicities or higher were reported. There were 29 grade two toxicities reported, with a majority being skin rash followed by fatigue, similar to what may be experienced with the longer five to six week course of treatment. The estimated three-year survival rate of the cancer not coming back to the breast area was 89.2 percent. The estimated three-year survival rate for the cancer not coming back and spreading beyond the breast was 90.3 percent.“While shorter courses of radiation therapy have been adopted in patients receiving radiation therapy to the breast alone after lumpectomy, there has not been adoption of shorter courses of treatment to the chest wall and lymph nodes after mastectomy. This trial demonstrated the safety of this shorter course approach in a prospective phase II study,” noted Haffty.Based on this study, a larger post-mastectomy randomized trial has been developed through the Alliance Cooperative Group with Haffty and current study investigators Matt Poppe of the Huntsman Cancer Institute and Atif J. Khan of Memorial Sloan Kettering Cancer Center leading the effort. In this phase III trial, a shorter course of radiation in the post-mastectomy, post-reconstruction setting will be compared to the more conventional five to six week course of treatment.Along with Haffty, Poppe and Khan, other investigators on the current study include Sharad Goyal, Rutgers Cancer Institute and Rutgers Robert Wood Johnson Medical School; Kristine E. Kokeny, Huntsman Cancer Institute, Thomas Kearney, Rutgers Cancer Institute and Rutgers Robert Wood Johnson Medical School; Laurie Kirstein, Memorial Sloan Kettering Cancer Center; Deborah Toppmeyer, Rutgers Cancer Institute and Rutgers Robert Wood Johnson Medical School; Dirk F. Moore and Chunxia Chen, both Rutgers Cancer Institute and Rutgers School of Public Health; and David K. Gaffney, Huntsman Cancer Institute.This work was supported in part by the National Institutes of Health Cancer Center Support Grant (P30CA072720) and the Breast Cancer Research Foundation (Haffty).For more information: www.jco.org FacebookTwitterLinkedInPrint分享 News | Neuro Imaging | August 16, 2019 ADHD Medication May Affect Brain Development in Children A drug used to treat attention-deficit/hyperactivity disorder (ADHD) appears to affect development of the brain’s… read more News | Mammography | August 14, 2019 Imago Systems Announces Collaboration With Mayo Clinic for Breast Imaging Image visualization company Imago Systems announced it has signed a know-how license with Mayo Clinic. The multi-year… read more Images of regions of interest (colored lines) in the white matter skeleton representation. Data from left and right anterior thalamic radiation (ATR) were averaged. Image courtesy of C. Bouziane et al. News | Patient Positioning Radiation Therapy | August 15, 2019 Mevion and C-RAD Release Integration for Improved Proton Therapy Treatment Quality Mevion Medical Systems and C-RAD announced the integration between the C-RAD Catalyst PT and the Mevion S250i proton… read more News | Artificial Intelligence | August 13, 2019 Artificial Intelligence Could Yield More Accurate Breast Cancer Diagnoses University of California Los Angeles (UCLA) researchers have developed an artificial intelligence (AI) system that… read more News | Proton Therapy | August 08, 2019 MD Anderson to Expand Proton Therapy Center The University of Texas MD Anderson Cancer Center unveiled plans to expand its Proton Therapy Center during a… read morecenter_img Related Content News | Pediatric Imaging | August 14, 2019 Ultrasound Guidance Improves First-attempt Success in IV Access in Children August 14, 2019 – Children’s veins read more Image courtesy of Imago Systems Catalyst PT image courtesy of C-RAD News | Radiation Therapy | May 02, 2017 Three-Week Radiation Therapy Treatment Post-Mastectomy Safe and Effective Rutgers Cancer Institute of New Jersey research shows low toxicity in shorter treatment course News | Radiation Therapy | August 16, 2019 Drug Accelerates Blood System’s Recovery After Radiation, Chemotherapy A drug developed by UCLA physician-scientists and chemists speeds up the regeneration of mouse and human blood stem… read more News | Brachytherapy Systems | August 14, 2019 Efficacy of Isoray’s Cesium Blu Showcased in Recent Studies August 14, 2019 — Isoray announced a trio of studies recently reported at scientific meetings and published in medica read more News | Radiation Therapy | August 15, 2019 First Patient Enrolled in World’s Largest Brain Cancer Clinical Trial Henry Ford Cancer Institute is first-in-the-world to enroll a glioblastoma patient in the GBM AGILE Trial (Adaptive… read more last_img